Physician profile
Gaurav Agarwal
NPI 1033432109
$4,616.44
in general payments reported to CMS, 2019-2025
32 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $286 · 2021: $620 · 2022: $946 · 2023: $463 · 2024: $761 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,294 · Education: $37.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.81 |
| Education | $37.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $825.81 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $509.95 | 2019-2024 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $387.59 | 2019-2025 | Jynarque |
| Amgen INC. | $355.94 | 2019-2025 | Krystexxa, Tavneos |
| Fresenius USA Marketing, INC. | $337.20 | 2019-2025 | Velphoro, Velphoro |
| Ardelyx, INC. | $325.14 | 2023-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $192.47 | 2021-2025 | |
| Glaxosmithkline, LLC. | $168.91 | 2020-2025 | Benlysta, Shingrix |
| Vifor Pharma, INC. | $167.70 | 2021-2023 | Veltassa |
| Travere Therapeutics, INC. | $139.25 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $123.33 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $121.02 | 2021-2022 | |
| Novo Nordisk INC | $106.78 | 2022-2025 | Ozempic, Rivfloza |
| Biosense Webster, INC. | $87.10 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $83.93 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $78.52 | 2019-2023 | Xarelto |
| Calliditas Therapeutics US INC. | $78.50 | 2022-2025 | Tarpeyo |
| Merck Sharp & Dohme LLC | $77.31 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $51.34 | 2019-2020 | |
| Lilly USA, LLC | $48.66 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $46.17 | 2022-2023 | Lupkynis |
| Daiichi Sankyo INC. | $41.40 | 2025 | Datroway |
| Horizon Therapeutics Plc | $36.39 | 2019-2023 | Krystexxa |
| Reflow Medical INC | $35.33 | 2025 | |
| Akebia Therapeutics INC | $32.30 | 2022-2025 | Vafseo |
| Scpharmaceuticals INC. | $30.57 | 2024 | |
| Cormedix INC. | $27.27 | 2025 | Defencath |
| Alnylam Pharmaceuticals INC. | $26.42 | 2021 | |
| Genzyme Corporation | $20.26 | 2021 | |
| Genentech USA, INC. | $19.43 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.36 | 2025 | Jardiance |
| Shire North American Group INC | $16.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaurav Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.